--- title: "Interferon beta-1a in children with MS is well tolerated. | Sutter Health" description: "Preliminary data indicate that weekly intramuscular injections of interferon-beta-1a are well tolerated in children with multiple sclerosis." url: "https://www.sutterhealth.org/research/publications/interferon-beta-1a-children-ms-tolerance-1055312304" --- 1. [Home](https://www.sutterhealth.org/) / 2. [Research](https://www.sutterhealth.org/research) / 3. [Research publications](https://www.sutterhealth.org/research/publications) / 4. Interferon beta-1a in children with MS is well tolerated. # Interferon beta-1a in children with multiple sclerosis is well tolerated. Waubant E, Hietpas J, Stewart T, Dyme Z, Herbert J, Lacy J, Miller C, Rensel M, Schwid S, & Goodkin D. _Neuropediatrics. 32(4):211-3._ 2001-08-01 ## Abstract BACKGROUND: Multiple sclerosis is a chronic demyelinating disease rare in children. Currently marketed disease modifying therapies are limited to adults. OBJECTIVE: To determine the tolerability of interferon beta-1a (IFNB-1a) 30 mcg injected intramuscularly once a week in children with clinically definite relapsing-remitting multiple sclerosis (RRMS). DESIGN/METHODS: A standardized questionnaire was sent to neurologists in the United States to determine the tolerability of IFNB-1a in patients younger than 16 years. RESULTS: Tolerability data were available for 9 of 33 children who were reported to initiate IFNB-1a. Mean age on initiating treatment was 12.7 years (range 8 - 15) and mean duration of therapy was 17 months (range 5 - 36). No patient discontinued therapy due to an adverse event. CONCLUSIONS: Preliminary data indicate that weekly intramuscular injections of IFNB-1a are well tolerated. [PubMed abstract](https://www.ncbi.nlm.nih.gov/pubmed/11571702) ## Research topics - [Child and Adolescent Health](https://www.sutterhealth.org/research-search-results?query=%22%5C%22Child+and+Adolescent+Health%5C%22%22) - [Disease Management](https://www.sutterhealth.org/research-search-results?query=%22%5C%22Disease+Management%5C%22%22) - [Neurological Disorders](https://www.sutterhealth.org/research-search-results?query=%22%5C%22Neurological+Disorders%5C%22%22) ## Related publications [View all publications](https://www.sutterhealth.org/research-search-results?verticalKey=research_publication) - Publication ### [Identification of short-term pharmacodynamic effects of interferon-beta-1a in multiple sclerosis subjects with broad- based phenotypic profiling.](https://www.sutterhealth.org/research/publications/pharmacodynamic-effects-interferon-beta-1a-ms-1055312290) Kantor AB, Deng J, Waubant E, Lin H, Becker CH, Lacy JR, Perrone AM, Bennett D, Goelz SE. J Neuroimmunol. 188(1-2):103-16. Epub 2007 Jul 5. 2007 Aug 01 - Publication ### [In reference to: Histologic assessment of thermal injury to tonsillectomy specimens: a comparison of electrocautery, coblation, harmonic scalpel, and tonsillotome.](https://www.sutterhealth.org/research/publications/histologic-assess-thermal-inj-tonsillect-specimen-1055312969) Hetzler D. Laryngoscope. 120(5):1077. doi: 10.1002/lary.20882. 2010 May 01 - Publication ### [A unique procedure for treatment of osteochondral lesions of the tarsal navicular: three cases in athletes.](https://www.sutterhealth.org/research/publications/unique-tx-osteochondral-lesions-tarsal-navicular-1055312365) Saxena A, Fullem BW. J Foot Ankle Surg. 52(2):249-53. doi: 10.1053/j.jfas.2012.10.019. Epub 2013 Jan 10. 2013 Mar 01 - Publication ### [Pseudoduplication of the optic disk.](https://www.sutterhealth.org/research/publications/pseudoduplication-optic-disk-1055312975) Sun Y, Ng JK, Gaynon MW. Retin Cases Brief Rep. 5(2):144-5. doi: 10.1097/ICB.0b013e3181cc2135. 2011 Apr 01 - Publication ### [Free latissimus dorsi flap used in treatment of cerebral aspergillosis: a case report and review of the literature.](https://www.sutterhealth.org/research/publications/latissimus-dorsi-flap-tx-cerebral-aspergillosis-1055312924) Antony AK, Hong RW, Amieva M, Taekman MS, Huhn SL, Karanas YL. Microsurgery. 23(4):313-6. 2003 Aug 20 [View all publications](https://www.sutterhealth.org/research-search-results?verticalKey=research_publication) ```json {"@context":"https://schema.org","@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org","logo":"https://www.sutterhealth.org/static/images/sutter-health-logo.svg","address":{"@type":"PostalAddress","streetAddress":"2200 River Plaza Drive","addressLocality":"Sacramento","addressRegion":"CA","postalCode":"95833","addressCountry":"US"},"areaServed":{"@type":"AdministrativeArea","name":"California"},"sameAs":["https://www.facebook.com/SutterHealth","https://www.instagram.com/sutterhealth/","https://x.com/SutterHealth","https://www.youtube.com/sutterhealth","https://www.linkedin.com/company/sutter-health","https://en.wikipedia.org/wiki/Sutter_Health"]} ``` ```json {"@context":"https://schema.org","@type":"BreadcrumbList","@id":"https://www.sutterhealth.org/research/publications/interferon-beta-1a-children-ms-tolerance-1055312304#breadcrumblist","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://www.sutterhealth.org/"},{"@type":"ListItem","position":2,"name":"Research","item":"https://www.sutterhealth.org/research"},{"@type":"ListItem","position":3,"name":"Research publications","item":"https://www.sutterhealth.org/research/publications"},{"@type":"ListItem","position":4,"name":"Interferon beta-1a in children with MS is well tolerated."}]} ``` ```json {"@context":"https://schema.org","@type":"MedicalScholarlyArticle","@id":"https://www.sutterhealth.org/research/publications/interferon-beta-1a-children-ms-tolerance-1055312304#medicalscholarlyarticle","name":"Interferon beta-1a in children with multiple sclerosis is well tolerated.","headline":"Interferon beta-1a in children with MS is well tolerated.","abstract":"BACKGROUND: Multiple sclerosis is a chronic demyelinating disease rare in children. Currently marketed disease modifying therapies are limited to adults. OBJECTIVE: To determine the tolerability of interferon beta-1a (IFNB-1a) 30 mcg injected intramuscularly once a week in children with clinically definite relapsing-remitting multiple sclerosis (RRMS). DESIGN/METHODS: A standardized questionnaire was sent to neurologists in the United States to determine the tolerability of IFNB-1a in patients younger than 16 years. RESULTS: Tolerability data were available for 9 of 33 children who were reported to initiate IFNB-1a. Mean age on initiating treatment was 12.7 years (range 8 - 15) and mean duration of therapy was 17 months (range 5 - 36). No patient discontinued therapy due to an adverse event. CONCLUSIONS: Preliminary data indicate that weekly intramuscular injections of IFNB-1a are well tolerated.","description":"Preliminary data indicate that weekly intramuscular injections of interferon-beta-1a are well tolerated in children with multiple sclerosis.","keywords":["Child and Adolescent Health","Disease Management","Neurological Disorders"],"datePublished":"2001-08-01","url":"https://www.sutterhealth.org/research/publications/interferon-beta-1a-children-ms-tolerance-1055312304","inLanguage":"en-US","identifier":[{"@type":"PropertyValue","propertyID":"PMID","value":"11571702"}],"sameAs":["https://pubmed.ncbi.nlm.nih.gov/11571702/"],"isPartOf":{"@type":"Periodical","name":"Neuropediatrics"},"author":[{"@type":"Person","name":"Waubant E"},{"@type":"Person","name":"Hietpas J"},{"@type":"Person","name":"Stewart T"},{"@type":"Person","name":"Dyme Z"},{"@type":"Person","name":"Herbert J"},{"@type":"Person","name":"Lacy J"},{"@type":"Person","name":"Miller C"},{"@type":"Person","name":"Rensel M"},{"@type":"Person","name":"Schwid S"},{"@type":"Person","name":"Goodkin D"}],"sourceOrganization":{"@type":"MedicalOrganization","name":"Palo Alto Medical Foundation Research Institute"},"about":[{"@type":"DefinedTerm","name":"Child and Adolescent Health","url":"https://www.sutterhealth.org/research-search-results?facets=%5B%7B%22i%22%3A%22c_researchTopics.name%22%2C%22v%22%3A%5B%22Child+and+Adolescent+Health%22%5D%7D%5D&verticalKey=research_publication"},{"@type":"DefinedTerm","name":"Disease Management","url":"https://www.sutterhealth.org/research-search-results?facets=%5B%7B%22i%22%3A%22c_researchTopics.name%22%2C%22v%22%3A%5B%22Disease+Management%22%5D%7D%5D&verticalKey=research_publication"},{"@type":"DefinedTerm","name":"Neurological Disorders","url":"https://www.sutterhealth.org/research-search-results?facets=%5B%7B%22i%22%3A%22c_researchTopics.name%22%2C%22v%22%3A%5B%22Neurological+Disorders%22%5D%7D%5D&verticalKey=research_publication"}],"mainEntityOfPage":{"@type":"WebPage","@id":"https://www.sutterhealth.org/research/publications/interferon-beta-1a-children-ms-tolerance-1055312304","breadcrumb":{"@id":"https://www.sutterhealth.org/research/publications/interferon-beta-1a-children-ms-tolerance-1055312304#breadcrumblist"}}} ```